Kornimate/medical-research-clean huggingface dataset:
a comparison of infection rates between two surgical sites

Conditions: Corneal Toxicity; Ototoxicity; Surgical Site Infection

Summary: does the use of chlorhexidine scrub prior to cutaneous surgery on the face increase the chances of toxicity to the eyes or ears? in addition, does the us eof chlorhexidine scrub on the face prior to cutaneous surgery decrease the chances of a post-operative wound infection?

the intent of this proposed prospective observational cohort study is to determine if there is a difference in the incidence of corneal toxicity and/or ototoxicity in study subjects undergoing mohs micrographic surgery (mms) on the face if a povidone-iodine preparation is used pre-operatively as compared to a chlorhexidine-alcohol preparation. it has recently been found that the use of a chlorhexidine-alcohol preparation is superior to the use of a povidone-iodine preparation in preventing post-operative surgical-site infections (ssi) in patients undergoing clean-contaminated surgery. however, the use of chlorhexidine on the face has previously been associated with corneal toxicity and ototoxicity. this study will help to further define previously reported risks of corneal toxicity and ototoxicity associated with the use of a chlorhexidine solution on the face.

Eligibility criteria:
inclusion criteria: * patients undergoing an outpatient cutaneous surgical procedure on the face. exclusion criteria: * those who do not consent to participation * those undergoing cutaneous surgery for a lesion on the eyelid margin * patients with a history of ongoing eye pain * history of a pre-existing corneal ulcer within 12 months prior to surgery * history of a perforated tympanic membrane * patients with an active infection at the surgical site at the time of surgery. * if post-operative follow-up is not completed, the study subject will be excluded from the analysis.

Keywords: surgical site infection corneal toxicity ototoxicity povidone-iodine chlorhexidine-alcohol
comparing immune responses to topical imiquimod

Conditions: Actinic Keratoses

Summary: the study is a basic science research study that is designed to characterize and compare the immune response in individuals who are designated as abo blood group secretors, meaning they have a functional copy of the fut2 gene versus those patients who are designated abo non-secretors after application of topical imiquimod to these patients.


Eligibility criteria:
inclusion criteria: * individuals between 18 to 85 years of age * patients with a diagnosis that will result in treatment with imiquimod as standard of care, specifically actinic keratosis exclusion criteria: * younger than 18 years or older than 85 years. * history of hypersensitivity/ allergic reaction or adverse reaction to imiquimod * individuals with a diagnostic biopsy and supportive histology of a cutaneous immune-mediated disease (e.g. psoriasis and mycosis fungoides, etc.) or diseases of the hematopoietic system, liver and the gastrointestinal tract (e.g. aplastic anemia, crohn's disease, ulcerative colitis, primary sclerosing cholangitis (psc), primary biliary cirrhosis, acute and chronic graft versus host disease (gvhd)). * individuals with autoantibodies plus objective evidence of end organ damage related to a cutaneous immune-mediated disease (e.g. psoriasis and mycosis fungoides, etc.) or diseases of the hematopoietic system, liver and the gastrointestinal tract (e.g. aplastic anemia, crohn's disease, ulcerative colitis, primary sclerosing cholangitis (psc), primary biliary cirrhosis, acute and chronic graft versus host disease (gvhd)). * individuals with a history of serious infection within the last 6 months. * individuals with tuberculosis, hiv, or hepatitis b, or c. * patients unable to provide consent * incarcerated individuals

Keywords: imiquimod aldara
evaluation of apricoxib (selective cyclooxygenase 2 inhibition) in modulating t regulatory cells of patients with early stage non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the primary objective for this trial is to determine the biological ability of apricoxib to decrease t reg cells in the peripheral blood and tumor infiltrating lymphocytes in subjects compared to those who have not in subjects with early stage non-small cell lung cancer (nsclc). the secondary objectives are to determine the efficacy of apricoxib to inhibit cd4+cd25+ t reg and foxp3 function and exploration of cox-2 dependent biomarkers of apoptosis resistance, angiogenesis, invasion, and immunity.


Eligibility criteria:
inclusion criteria: * adults over the age of 18 capable of giving informed consent. radiographic findings suspicious for primary lung cancer or pathologically confirmed nsclc which is surgically resectable and radiographically early stage (stage i and ii). * ecog performance status of 0, 1, or 2 (see appendix a). * ineligible for or refuse preoperative chemotherapy or chemoradiation therapy * normal renal function (defined as serum creatinine ≤ 2 mg/dl or creatinine clearance ≥ 60 ml/min/1.73m2). * normal liver function (defined as total bilirubin ≤ 1.5 x uln, sgot \& sgpt ≤ 2.5 xuln). * negative pregnancy test prior to initiation of treatment and adequate contraception throughout treatment. * preoperative pulmonary function test (pft) with fev1 and d lco ≥ 60% or predicted postoperative fev1 and dlco ≥ 40% based on quantitative lung perfusion scan * must be able to come off anticoagulants and have normal coagulation studies (ptt \< 40 seconds and inr \< 1.4) prior to planned surgery. * for subjects on cox-2 inhibitors or other nsaids prior to study initiation, cessation of the drug for 1 week prior to apricoxib administration is required for study enrollment. exclusion criteria: * radiation therapy, chemotherapy, non-cytotoxic investigational agents, or corticosteroids within 4 weeks of initiating treatment. * comorbid disease or a medical condition that would impair the ability of the subject to receive or comply with the study protocol. * hypersensitivity to apricoxib, sulfonamides, aspirin, or other nsaids or to any reagents used in the study. * previous history of gastrointestinal ulceration, bleeding, or perforation. * required concurrent use of cox-2 inhibitors or other nsaids during apricoxib administration. * chronic or concurrent use of steroids (topical steroids are acceptable if medically indicated). * pregnant or nursing women. * evidence of nyha class iii or greater cardiac disease. * history of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within 12 months of initiating treatment. * history of heart surgery for coronary artery disease. * known hiv infection or aids.
evaluation the effect of acetyl-l-carnitine in patients with mild cognitive impairment accompanied with chronic cerebrovascular disease

Conditions: Mild Cognitive Impairment

Summary: the purpose of this study is to evaluate the efficacy of acetyl-l-carnitine in patient with mild cognitive impairment associated with chronic cerebrovascular disease.


Eligibility criteria:
inclusion criteria: * age between 55 and 85 years old * patients with chronic cerebrovascular disease, who have modified fazekas scale grade 2 \~ 3 * patients wtih a diagnosis of mci * moca-k of 23 or less * patients who provided a signed written informed consent form exclusion criteria: * patiens who are uneducated or illiterate * patiens previously treated with dementia * patients who received a nootropic agent or thyroid hormone within 4 weeks of visit 1 * patients with cognitive impairment due to diseases other than cerebrovascular disease * patients with severe depression, schizophrenia, alcoholism, and drug dependence
influence of collagen cone on jumping gap management around dental implants

Conditions: Tooth Loss

Summary: the present study will be performed to assess the clinical and radiographic effect of collagen cone for bone growth in immediate implants.

improve width and length of buccal plate of alveolar bone, bone density around dental implamts in esthetics zone.

Eligibility criteria:
inclusion criteria: * patients aged between 30-50 years. * good general health. * adequate bone volume at the implant site. * non-compromised periodontal status. exclusion criteria: * presence of parafunctional habits (e.g., bruxism, clenching, excessive gum chewing, lip or fingernail biting). * smokers. * patients receiving chemotherapy or radiotherapy. * alcohol or drug abuse. * pregnancy and lactation. * use of drugs that may affect bone metabolism.

Keywords: immediate implant collagen cone esthatic zone jumping gap
smart technology for weight loss and metabolic health

Conditions: Obesity; Overweight; Prediabetes; Weight Loss; Lifestyle

Summary: the study will evaluate whether a technology-based lifestyle intervention program using primarily a smartphone platform is an acceptable and effective way for treating obesity. the goal of the program is to achieve weight loss and enhance the health of overweight or obese subjects by improving their diet and activity via smartphone applications as compared with conventional in-person weight management programs.


Eligibility criteria:
inclusion criteria: * overweight or obese bmi 25-42 kg/m2 * employed in sedentary occupations * own a personal smartphone with unlimited data plan or \>4 gigabyte data * proficient with use of smartphone applications and technology with current daily usage * ability to engage in moderate intensity exercise * weight stability for the last 2 months * participants must be willing to comply with all study-related procedures exclusion criteria: * current or planned pregnancy * cardiovascular, pulmonary, renal disease, joint disease * uncontrolled thyroid disease * history of eating disorders, psychiatric disease * history of substance abuse or dependence in the last 1 year * diabetes * shift work * previous weight loss surgery * use of weight loss drugs/diet/program in the last 6 weeks * inability to increase walking as a form of exercise and to engage in moderate intensity exercise * other conditions or medications that affect body weight/appetite/metabolism * serious or unstable medical or psychological conditions that would compromise the subject's safety for successful participation * incapable of adhering with an intensive lifestyle intervention using technology and smartphone applications

Keywords: obesity overweight prediabetes smartphone application technology weight loss lifestyle intervention
pain education program in the sport population

Conditions: Pain; Sports; Education

Summary: this study is designed to evaluate the effects of a pain neuroscience education program in pain perception, wellness and pain catastrophizing of youth athletes. for this, an experimental study with an intervention group (ig) and a control group (cg) is designed. during 12 weeks of the 2022-2023 season, cg will receive a self-care education program, with information about health habits in the sport (rest, nutrition, body care and recovery). meanwhile, ig will also receive a pain neuroscience education program, with information about biological, psychological and perceptual aspect of pain in the sports context. the study will be developed in the sport high performance centre of balearic islands, from january to may. all athletes from this sports centre will be invited to participate in the study throughout an e-mail invitation from their sport regional federation. prior to the beginning of the study, all participants will sign the inform consent. the ethical committee of the local university approved this study (280cer22). one week before intervention period, all athletes will be required to complete questionnaire about sociodemographic and sportive data (age, sex, and sport experience). body mass and height will be also evaluated. also, all the athletes will be required to complete three questionnaires about pain level, wellness and pain catastrophizing. pain level and wellness will be evaluated prior to the start of the intervention and weekly, until finishing the intervention period. the pain catastrophizing level will be evaluated before and after the intervention period of the study. we hypothesized that those athletes who receive the pain neuroscience education program will increase wellness and decrease pain level and catastrophizing perception compared to those athletes who received a self-care educational program.


Eligibility criteria:
inclusion criteria: * to have at least 14 years old * to have at least 2 years of experience in the sport exclusion criteria: * to have sustained an injury during the previous 6 months to start of the study * to have sustained a surgery during the previous 12 months to start of the study

Keywords: pain education athlete pain catastrophizing
functional mr-guided stereotactic body radiation therapy of prostate cancer

Conditions: Prostatic Neoplasms

Summary: to improve radiation therapy of prostate cancer, the investigators must be able to accurately identify the tumour. by using advanced functional imaging techniques available on state-of-the-art mri scanners to clearly show the specific location of the tumour inside the prostate, the investigators can use advanced radiation therapy techniques to specifically target the tumor and control it with as few radiotherapy clinic visits as possible. this is different than current techniques which treat the whole prostate gland to the same dose, delivered over 7-8 weeks of daily radiotherapy visits. by increasing the radiation dose to the active tumor while still maintaining adequate radiation dose to the rest of the prostate, the investigators hope to better control prostate cancer and reduce complications to nearby normal tissues.

this project combines advances in functional imaging of prostate cancer and hypofractionation through stereotactic body radiotherapy (sbrt), with an aim to improve tumour control and reduce or maintain normal tissue complications. the strategy will make use of the combined effectiveness of several functional imaging approaches to identify the dominant lesion(s) within the prostate. an sbrt treatment plan will be designed which utilizes 5 fractions to treat the entire prostate gland with an additional boost to the dominant lesion. the lower dose to the entire prostate should reduce normal tissue complications but still be effective in treating prostate cancer while the increased dose to the dominant lesion should improve tumour control. the use of only 5 fractions will reduce the number of patient visits, thus reducing overall treatment costs.

Eligibility criteria:
inclusion criteria: * informed consent * age \>18 years * histologically confirmed and centrally reviewed prostate adenocarcinoma based * psa within 60 days * high risk prostate cancer defined as any one of: clinical stage \>= t3, gleason score \>= 8, or psa \>=20 and \<50 ng/ml. exclusion criteria: * evidence of lymph node metastasis * evidence of distant metastases * prior pelvic radiotherapy or brachytherapy * previous radical prostatectomy, cryotherapy, or high-frequency ultrasound * unable to undergo gold seed insertion * immunosuppressive medications * inflammatory bowel disease * unable to undergo mri * previous bilateral orchiectomy * previous hormonal therapy including lhrh agonists (leuprolide, goserelin), lhrh antagonists (degarelix), anti-androgens (bicalutamide, flutamide, nilutamide), surgical castration, and estrogens * previous finasteride within 14 days. * previous dutasteride within 180 days.

Keywords: prostatic neoplasms radiotherapy dose fractionation magnetic resonance imaging
radial vs. state-of-the-art femoral access for bleeding and access site complication reduction in cardiac catheterization (rebirth)

Conditions: Patient Satisfaction; Vascular Access Complication

Summary: this is a phase iv, prospective, open label, randomized-controlled study that will compare radial access with state-of-the-art femoral access in patients without st-segment elevation acute myocardial infarction undergoing cardiac catheterization. subjects will be randomized 1:1 into 2 treatment groups: radial access and state-of-the-art femoral access. randomization will be performed in blocks of 50 per site. similarly, a second sub-randomization will be performed in the femoral access group into use of 18 vs 21 gauge needles, also in a 1:1 fashion.


Eligibility criteria:
inclusion criteria: * age 18 years and older * undergoing diagnostic angiography for ischemic symptoms with possible pci, or undergoing planned urgent or elective pci * has provided informed consent and agrees to participate * patients must be equally eligible to undergo cardiac catheterization via radial or femoral access exclusion criteria: * primary pci for stemi * planned right heart catheterization * valvular heart disease requiring valve surgery within 30 days after the index procedure * hemodialysis access (arteriovenous fistula or graft) in the arm to be used for pci in case of assignment to radial approach (the opposite arm may be used for radial access if a dialysis graft is present in one) * peripheral arterial disease prohibiting vascular access * presence of bilateral internal mammary artery coronary bypass grafts * international normalized ratio ≥1.5 while treated with oral vitamin k antagonists (i.e. warfarin) receipt of oral factor xa or iia inhibitors ≤24 h before procedure * planned staged pci within 30 days after index procedure. * any planned surgeries within 30 days after index procedure * planned dual arterial access (for example for chronic total occlusion pci) * coexisting conditions that limit life expectancy to less than 30 days * positive pregnancy test
long term outcomes after laparoscopic intersphincteric resection with total mesorectal excision for low rectal cancer.

Conditions: Low Rectal Cancer

Summary: through a double blinded study, patients with low rectal cancer will be randomized into two equal groups to compare between the 5 year disease free survival as a primary outcome measure.


Eligibility criteria:
inclusion criteria: * low rectal cancer below 5 cm from the anal verge * fit for laparoscopic total mesorectal excsion * t2, t3 rectal cancer * no distant metstasis exclusion criteria: * t1, and t4 * distant metastasis * tumor infiltrating the dentate line * unwilling to participate

Keywords: intersphincteric resection laparoscopic rectal rescetion total mesorectal excsison
prospective 4d cta of bav competence

Conditions: Bicuspid

Summary: the study involves annual 4d cta imaging of the bicuspid aortic valve for a period of 5 years. cta is often standard of care for bav patients, but patients in this study will receive a higher radiation dose with a 4d imaging protocol. there may also be patients enrolled in the study who have a 4d cta for research purposes when a routine cta is not required for clinical care.

the bicuspid aortic valve (bav) is the most common congenital heart disease. the purpose of this study is to better understand the anatomy of physiologically normal, or competent, bavs without stenosis or insufficiency (ai) in order to support evidence-based standardization of bav repair surgery. men and women over 18 years of age with a diagnosis of bav and minimal aortic valve calcification at baseline will undergo annual 4d computed tomography angiography (cta) scans, routine transthoracic echocardiograms, and history and physical assessments over the course of the 5-year study period. patients who are pregnant, have renal insufficiency (creatinine 2 mg/dl), or who have a contraindication to intravenous contrast will be excluded. patients will be stratified into study groups according to baseline ai: approximately half of patients will have no to mild ai at baseline and the other half will have moderate to severe ai at baseline. anatomical measurements will be obtained from the 4d cta scans and analyzed at each phase of the cardiac cycle, as well as longitudinally. the 4d cta imaging and analysis will not impact medical care of the study participants; the anatomical measurements will be used in the future as evidence-based standards for determining valve repair candidacy for bav patients with ai.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * documented bicuspid aortic valve identified via clinical imaging (e.g., ct, mri, or echocardiogram) with minimal calcification at the time of enrollment * participant must sign the informed consent form exclusion criteria: * pregnancy (determined by point of care urine pregnancy test) * renal failure (estimated glomerular filtration rate (egfr) \< 30), precluding them from receiving intravenous contrast) * documentation of previous intravenous contrast allergy (unless they are having a ct with steroid preparation as part of routine clinical care) * previous aortic valve replacement

Keywords: bicuspid aortic valve
businesses that care - zacatecas

Conditions: Alcohol Drinking

Summary: the purpose of this study is to develop and implement a community-based prevention initiative to prevent youth alcohol use and abuse in zacatecas, mexico.


Eligibility criteria:
inclusion criteria for parent participants: * must be 18 years or older who are actively working at one of the four btc participating companies in zacatecas, mexico. * must be residents of the cities of zacatecas or guadalupe, in the state of zacatecas, mexico. * workers who are illiterate or otherwise literary challenged are included. * must have at least one child (biological, step or adopted) between the ages of 8 and 16 years of age. exclusion criteria for parent participants: * doesn't speak spanish. inclusion criteria for children participants: * must be a child (biological, step or adopted) of a btc employee who participated in the study. * must be between the age of 11 to 16 years. exclusion criteria for children participants: * doesn't speak spanish.

Keywords: underage drinking
s9346a blood samples from patients with metastatic prostate cancer previously treated with bicalutamide and goserelin

Conditions: Prostate Cancer

Summary: rationale: studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment. purpose: this research study is studying blood samples from patients with metastatic prostate cancer previously treated with bicalutamide and goserelin.

objectives: * to test the association between serum psa response (\< 4 ng/ml) at 7 months with inherited variability of germline single nucleotide polymorphisms, in a set of candidate genes, in patients with metastatic prostate cancer treated with combination induction androgen-deprivation therapy comprising bicalutamide and goserelin. outline: dna extracted from whole blood or serum samples is analyzed for inherited variability of germline single nucleotide polymorphisms.

Eligibility criteria:
disease characteristics: * diagnosed with metastatic prostate cancer * accrued to swog-9346 and received androgen-deprivation therapy (adt) * must have serum psa values from the beginning to the end of 8 courses of adt * must have whole blood or serum samples available patient characteristics: * caucasian and african-american participants prior concurrent therapy: * see disease characteristics

Keywords: recurrent prostate cancer stage iv prostate cancer